scholarly journals Endovascular embolisation of the middle meningeal artery to treat chronic subdural haematomas: effectiveness, safety, and the current controversy. A systematic review

Author(s):  
R. Martinez-Perez ◽  
N. Rayo ◽  
A. Tsimpas
2021 ◽  
pp. neurintsurg-2021-017352
Author(s):  
Natasha Ironside ◽  
Candice Nguyen ◽  
Quan Do ◽  
Beatrice Ugiliweneza ◽  
Ching-Jen Chen ◽  
...  

Middle meningeal artery (MMA) embolization has been proposed as a minimally invasive treatment for chronic subdural hematoma (cSDH). The aim of this systematic review and meta-analysis is to compare outcomes after MMA embolization versus conventional management for cSDH. We performed a systematic review of PubMed, Embase, Oxford Journal, Cochrane, and Google Scholar databases from April 1987 to October 2020 in accordance with PRISMA guidelines. Studies reporting outcomes after MMA embolization for ≥3 patients with cSDH were included. A meta-analysis comparing MMA embolization with conventional management was performed. The analysis comprised 20 studies with 1416 patients, including 718 and 698 patients in the MMA embolization and conventional management cohorts, respectively. The pooled recurrence, surgical rescue, and in-hospital complication rates in the MMA embolization cohort were 4.8% (95% CI 3.2% to 6.5%), 4.4% (2.8% to 5.9%), and 1.7% (0.8% to 2.6%), respectively. The pooled recurrence, surgical rescue, and in-hospital complication rates in the conventional management cohort were 21.5% (0.6% to 42.4%), 16.4% (5.9% to 27.0%), and 4.9% (2.8% to 7.1%), respectively. Compared with conservative management, MMA embolization was associated with lower rates of cSDH recurrence (OR=0.15 (95% CI 0.03 to 0.75), p=0.02) and surgical rescue (OR=0.21 (0.07 to 0.58), p=0.003). In-hospital complication rates were comparable between the two cohorts (OR=0.78 (0.34 to 1.76), p=0.55). MMA embolization is a promising minimally invasive therapy that may reduce the need for surgical intervention in appropriately selected patients with cSDH. Additional prospective studies are warranted to determine the long-term durability of MMA embolization, refine eligibility criteria, and establish this endovascular approach as a viable definitive treatment for cSDH.


2019 ◽  
Vol 186 ◽  
pp. 105464 ◽  
Author(s):  
Jordan Court ◽  
Charles J Touchette ◽  
Christian Iorio-Morin ◽  
Harrison J. Westwick ◽  
François Belzile ◽  
...  

2020 ◽  
Vol 49 (4) ◽  
pp. E7
Author(s):  
Alba Scerrati ◽  
Jacopo Visani ◽  
Luca Ricciardi ◽  
Flavia Dones ◽  
Oriela Rustemi ◽  
...  

OBJECTIVEChronic subdural hematoma (CSDH) is one of the most common neurosurgical pathologies, typically affecting the elderly. Its incidence is expected to grow along with the aging population. Surgical drainage represents the treatment of choice; however, postoperative complications and the rate of recurrence are not negligible. For this reason, nonsurgical alternatives (such as middle meningeal artery embolization, steroids, or tranexamic acid administration) are gaining popularity worldwide and need to be carefully evaluated, especially in the elderly population.METHODSThe authors performed a systematic review according to PRISMA criteria of the studies analyzing the nonsurgical strategies for CSDHs. They collected all papers in the English language published between 1990 and 2019 by searching different medical databases. The chosen keywords were “chronic subdural hematoma,” “conservative treatment/management,” “pharmacological treatment,” “non-surgical,” “tranexamic acid,” “dexamethasone,” “corticosteroid,” “glucocorticoid,” “middle meningeal artery,” “endovascular treatment,” and “embolization.”RESULTSThe authors ultimately collected 15 articles regarding the pharmacological management of CSDHs matching the criteria, and 14 papers included the endovascular treatment.CONCLUSIONSThe results showed that surgery still represents the mainstay in cases of symptomatic patients with large CSDHs; however, adjuvant and alternative therapies can be effective and safe in a carefully selected population. Their inclusion in new guidelines is advisable.


Neurosurgery ◽  
2019 ◽  
Vol 66 (Supplement_1) ◽  
Author(s):  
Fareed Jumah ◽  
Muhammad Osama ◽  
Abdurrahman Islim ◽  
Ammar Jumah ◽  
Devi Prasad Patra ◽  
...  

Abstract INTRODUCTION Refractory chronic subdural hematomas (cSDH) constitute a challenging entity that neurosurgeons face frequently nowadays, especially in fragile elderly populations. Middle meningeal artery embolization (MMAE) has emerged in the past years as a promising treatment option. However, solid evidence is still lacking due to paucity of studies and small sample sizes. METHODS We conducted a systematic review and meta-analysis (MA) in compliance with the PRISMA guidelines to evaluate the efficacy and safety of MMAE compared with conventional treatments for refractory or SDH. Four databases were searched up to March 2019. Using a random-effects model, meta-analyses of proportions and risk difference were conducted on outcomes including recurrence, need for surgical rescue, and complications RESULTS A total of 12 studies (177 patients) were included. Majority (69%) were males with weighted mean age of 71 + −19.5 yr. Rate of chronic alcoholism was 15%, cerebral atrophy 39%, use of anticoagulants/antiplatelets 52%, and history of head trauma 55%. Weighted mean hematoma thickness was 17.9 + −13.3 mm. In embolized patients across 12 studies, proportion MA showed rate of treatment failure to be 2.9% (95% CI = 0.5%-5.2%, I2 = 0%), need for surgical rescue 2.7% (95% CI = 0.4%-5%, I2 = 0%), and embolization-related complications 1.2% (95% CI 0.3%-2.7%, I2 = 0%). Meta-analysis of risk-difference between embolized and nonembolized patients in three double-armed cohort studies showed a 26% lower risk of failure in MMAE (95% CI 21%-31%, I2 = 0, Cochran Q = 0.64) that was statistically significant (P < 0.001). Similarly, in the embolized group, the need for surgical rescue was 20% less (95% CI = 12%-27%, I2 = 12.4, Cochran Q = 2.28) and complications 3.6% less (95% CI 1%-6%, I2 = 0, Cochran Q = 0.31) than in conventional groups, both of which achieved statistical significance CONCLUSION Although MMAE appears to be a promising treatment for refractory or cSDH, drawing definitive conclusions remains limited by paucity of data. Large, prospective trials are needed to compare embolization to conventional treatments, like watchful waiting, medical management, or surgical evacuation. More extensive research of MMAE could begin a new era in the minimally invasive management of cSDH.


2020 ◽  
Vol 162 (4) ◽  
pp. 777-784 ◽  
Author(s):  
Mette Haldrup ◽  
Baskaran Ketharanathan ◽  
Birgit Debrabant ◽  
Ole Søndergaard Schwartz ◽  
Ronni Mikkelsen ◽  
...  

2019 ◽  
Vol 122 ◽  
pp. 613-619 ◽  
Author(s):  
Aditya Srivatsan ◽  
Alina Mohanty ◽  
Fábio A. Nascimento ◽  
Muhammad U. Hafeez ◽  
Visish M. Srinivasan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document